NATIONAL INSTITUTES OF HEALTH has floated a tender for Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional). The project location is USA and the tender is closing on 13 Nov 2020. The tender notice number is PAR-18-745, while the TOT Ref Number is 22331091.
Bidders can have further information about the Tender and can request the complete Tender document by Registering on the site.
Procurement Summary
Country : USA
Summary : Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)
Deadline : 13 Nov 2020
Other Information
Notice Type : Tender
TOT Ref.No.: 22331091
Document Ref. No. : PAR-18-745
Competition : ICB
Financier : Self Financed
Purchaser Ownership : -
Tender Value : Refer Document
Purchaser's Detail
Purchaser : NATIONAL INSTITUTES OF HEALTH NIH OER WebmasterFBOWebmaster@OD.NIH.GOV USA Email :FBOWebmaster@OD.NIH.GOV
Tender Details
Tender are invited for Addressing the Challenges of the Opioid Epidemic in Minority Health and Health Disparities Research in the U.S. (R21 Clinical Trial Optional)
CFDA Number : 93.273 -- Alcohol Research Programs93.279 -- Drug Abuse and Addiction Research Programs93.307 -- Minority Health and Health Disparities Research93.313 -- NIH Office of Research on Women``s Health93.865 -- Child Health and Human Development Extramural Research93.866 -- Aging Research
Cost Sharing or Matching Requirement : No
Closing Date for Applications: Nov 13, 2020
Posted Date : Apr 10, 2018
Description: The purpose of this Funding Opportunity Announcement (FOA) is to encourage developmental and exploratory research focused on determining the mechanisms for the variation in the prevalence of Opioid Use Disorder (OUD), and understanding and reducing disparities in opioid care in minority health and health disparity populations in the U.S. This initiative will also seek to identify multi-level intervention strategies at the institutional and systems level for addressing OUD in these populations.